DEEPLY COMMITTED TO PATIENTS
Our Story
TG Therapeutics was founded with one goal in mind – to leverage scientific advances to develop the best possible treatment options for patients.
Today, our focus is on translating that deep understanding of B-cells developing therapies for autoimmune diseases, with a current focus on multiple sclerosis (MS). These are conditions in which dysregulated B-cell activity plays a critical role in driving inflammation and tissue damage. By targeting B-cells with precision, our goal is to meaningfully alter the course of disease and improve how treatment fits into patients’ lives.
How We Work
- Find the right science early. We identify programs grounded in strong science and a clear therapeutic rationale, then move quickly to generate decisive clinical data.
- Design for real-world use. We develop therapies that not only work but work better for patients—reducing treatment burden and increasing flexibility.
- Focus where we can lead. We invest where our expertise can have the greatest impact.
- Build with partners. We collaborate with scientists, clinicians, and companies worldwide to advance innovative ideas that can help patients sooner.
What Drives Us
Every decision begins with one question: Will this matter to people living with Multiple Sclerosis or another autoimmune disease we are seeking a treatment for?
That question keeps us focused on scientific rigor, clinical relevance, and transparency in how we operate. It also reminds us why we do this work—to deliver therapies that make a meaningful difference for people living with autoimmune diseases like MS.
